Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
AI-developed drug will be in trials by year-end, says Google’s Hassabis
Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its ...
FiercePharma2d
Lilly, Merck team with Purdue University to pioneer new drug production methods
Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...
STAT12d
Spurred by AI’s possibilities, Eli Lilly and Andreessen Horowitz partner on $500M venture fund
Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of ...
FierceBiotech12d
Eli Lilly, Andreessen Horowitz link up on $500M biotech venture fund
Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the ...
STAT9d
Eli Lilly acquires cancer program from Scorpion Therapeutics in $2.5B deal
Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it ...
Yahoo8d
Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow
Here's What History Has to Say. Billionaire Investor Bill Ackman Just Went All In On One of His Favorite Stocks: He Plans to Hold It "Forever" AI Agents Are Coming in 2025. Here's My Top Stock ...
Lilly to pay $2.5B for Boston biotech's lead cancer drug
Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...
The Motley Fool5d
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered ... Meanwhile, its non-weight loss drug portfolio is also growing nicely. From a valuation perspective, Lilly trades at a forward price-to-earnings (P/E) of 25.4 ...